Mainz Biomed Demonstrates 100% Sensitivity and 95% Specificity of mRNA Pancreatic Cancer Test
Mainz Biomed will present at Digestive Disease Week 2026 in Chicago a poster on its blood-based mRNA signature test for pancreatic ductal adenocarcinoma with 100% sensitivity and 95% specificity. The findings confirm the algorithm’s biomarker selection and advance PancAlert PCR multiplex screening toward clinical readiness for early-stage pancreatic cancer detection.
1. Presentation at Digestive Disease Week
Mainz Biomed will present a poster on February 24 at Digestive Disease Week 2026 in Chicago titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS,” marking its participation in a leading industry conference.
2. Discovery Study Results
The company reported 100% sensitivity and 95% specificity in its blood-based mRNA signature from a discovery study, demonstrating the algorithm’s ability to accurately identify pancreatic neoplasms in blood samples.
3. Progress Toward PancAlert Launch
These results support development of its PancAlert real-time PCR multiplex screening test aimed at early-stage pancreatic cancer detection, advancing the product toward market readiness.
4. Company Background and Pipeline
Mainz Biomed specializes in molecular genetics diagnostics and is developing a portfolio of screening tests for life-threatening conditions, with PancAlert as its leading candidate for pancreatic cancer.